Biomea Fusion, Inc. (BMEA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
The Schall Law Firm Is Looking Into Whether Biomea Fusion Inc Violated Securities Regulations And Impacted Investors Are Invited To Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.
Biomea Fusion, Inc. Being Investigated on Behalf of Biomea Fusion, Inc. Investors; Contact Levi & Korsinsky For Details
NEW YORK, NY / ACCESSWIRE / September 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biomea Fusion, Inc. ("Biomea Fusion, Inc.") (NASDAQ:BMEA) concerning possible violations of federal securities laws. Biomea issued a press release on June 6, 2024, announcing that it "has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.
Biomea Fusion, Inc. May Have Committed Securities Fraud And Stockholders Can Partake In An Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.
ATTENTION BMEA SHAREHOLDERS: Investors who lost money on Biomea Fusion, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
NEW YORK, NY / ACCESSWIRE / September 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biomea Fusion, Inc. ("Biomea Fusion, Inc.") (NASDAQ:BMEA) concerning possible violations of federal securities laws. Biomea issued a press release on June 6, 2024, announcing that it "has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.
The Schall Law Firm Has Launched An Inquiry Into Whether Biomea Fusion Inc Violated Securities Laws And Investor Participation Is Urged
LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.
BMEA ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Biomea Fusion, Inc. investment
NEW YORK, NY / ACCESSWIRE / September 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biomea Fusion, Inc. ("Biomea Fusion, Inc.") (NASDAQ:BMEA) concerning possible violations of federal securities laws. Biomea issued a press release on June 6, 2024, announcing that it "has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.
Biomea Fusion, Inc. Is Being Investigated By The Schall Law Firm For Engaging In Securities Related Impropriety And Shareholders Can Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.
Biomea Fusion, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - BMEA
NEW YORK, NY / ACCESSWIRE / September 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biomea Fusion, Inc. ("Biomea Fusion, Inc.") (NASDAQ:BMEA) concerning possible violations of federal securities laws. Biomea issued a press release on June 6, 2024, announcing that it "has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.
The Schall Law Firm Is Looking Into Biomea Fusion Inc's Possible Securities Fraud And Investors Should Join The Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Biomea Fusion, Inc. (BMEA) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / September 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biomea Fusion, Inc. ("Biomea Fusion, Inc.") (NASDAQ:BMEA) concerning possible violations of federal securities laws. Biomea issued a press release on June 6, 2024, announcing that it "has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.
Biomea Fusion Inc. May Have Violated Securities Laws And The Schall Law Firm Invites Shareholder Participation In An Investigation
LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.
Biomea Fusion, Inc. (BMEA) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / September 3, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biomea Fusion, Inc. ("Biomea Fusion, Inc.") (NASDAQ:BMEA) concerning possible violations of federal securities laws. Biomea issued a press release on June 6, 2024, announcing that it "has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.
